Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsSINGLE-DOSEStandard

KANJINTI

TRASTUZUMAB-ANNS

Standard Dose
150MG
Max Dose
Refer to approved labeling
Primary Use
Review priority: UNKNOWN Marketing status: Prescription
Summary

Approval overview KANJINTI is listed in Drugs@FDA under application 761073 (BLA).

Review priority: UNKNOWN Marketing status: Prescription Active ingredient TRASTUZUMAB-ANNS Form and strength VIAL;SINGLE-DOSE - 150MG Sponsor AMGEN INC Submission history Latest submission status date: 2024-12-19 00:00:00.

Structured Monograph

Clinical summary

Approval overview KANJINTI is listed in Drugs@FDA under application 761073 (BLA). Review priority: UNKNOWN Marketing status: Prescription Active ingredient TRASTUZUMAB-ANNS Form and strength VIAL;SINGLE-DOSE - 150MG Sponsor AMGEN INC Submission history Latest submission status date: 2024-12-19 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Prescription
  • • Review priority: UNKNOWN

Interaction Notes

  • No interaction notes stored yet.